
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay is forecasted to have strong growth prospects as shown by a 7x sales multiple, potential for reimbursement expansion and market access, and potential to drive equity value through minority stakes in other businesses. The company's recent virtual analyst and investor day highlighted multiple tailwinds, including the ongoing transformation of neuropsychiatry and the potential approval and launch of the Neurolief device. BrainsWay's option to acquire Neurolief further adds to its potential long-term growth opportunities.
Bears say
BrainsWay is facing a decrease in its net earnings and top-line revenue due to its modest performance, leading to the company's recent adjustment of its stock price target. Furthermore, the company's investment in Neurolief, while expected to drive future growth, may also impact its short-term profitability. As such, we maintain a negative outlook on the stock.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares